by Brian A. Francis, M.D., M.S
In the ten years since the FDA approval of selective laser trabeculoplasty for the treatment of open-angle glaucomas, the 10 unique features that have emerged are:
1. Selectivity and minimal tissue damage of target tissue,
2. Mechanism of action of increasing trabecular aqueous outflow facility,
3. Efficacy equal to that of the most potent class of glaucoma medications,
4. Excellent safety and side effect profile,
5. Ability to improve patient compliance,
6. Ability to decrease patient cost of treatment as well as societal economic burden of glaucoma treatment,
7. Success as an adjunctive treatment in patients who have failed medical or prior laser therapy,
8. Reduction of glaucoma medications in patients with medically controlled IOP (replacement therapy),
9. Reduction in diurnal IOP fluctuation, and
10. Repeatability of SLT in previously treated patients.
From the article "Ten Years of Selective Laser Trabeculoplasty" by Brian A. Francis, M.D., M.S., Associate Professor of Ophthalmology at the Doheny Eye Institute, Keck School of Medicine, University of Southern California.
Posted Tuesday, October 04, 2011 at
http://www.ophthalmologyweb.com/1319-AuthorProfile/1313-Brian-A-Francis-M-D-M-S/
**************************************************************
The Lumenis SLT Laser is available to ophthalmologists as a short- term laser rental.
Visit www.Option3.Biz
or call
Lauren Teton
Marketing Manager Option3 LLC
Westchester County, NY
914 764-0115
No comments:
Post a Comment